|
|
|
|
|
PARIS, FRANCE, 2023年9月12日 - (亞太商訊) - Ad Scientiam, a global leader in digital biomarkers, has announced a partnership with Sanofi to launch MS-DETECT, an international, multicenter, longitudinal study. MS-DETECT aims to evaluate the ability of MSCopilot(R), a medical software device, to detect early signs of disability worsening in people with multiple sclerosis (PwMS). The study will draw upon Ad Scientiam's expertise in MS and is financially supported by Sanofi.
Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that affects 2.8 million people worldwide. The disease is characterized by early inflammatory demyelination and subsequent neurodegeneration. Current clinical evaluation of PwMS relies mainly on the Expanded Disability Status Scale (EDSS), which has several limitations. To improve on these assessments, Ad Scientiam has developed MSCopilot(R), a software medical device that addresses four dimensions: ambulation/mobility, upper extremity function, cognition, and low-contrast visual acuity.
MS-DETECT's main objective is to determine MSCopilot(R)'s ability to identify subtle and early disability worsening. This will be performed by evaluating MSCopilot(R) individual and/or composite scores as compared to the Multiple Sclerosis Functional Composite (MSFC) and the EDSS.
"MS-DETECT is a pioneering large-scale longitudinal study that explores digital biomarkers for the early detection of disease progression. This study will provide important data to both clinicians and people living with MS," according to Dr. Saad Zinai, Chief Medical Officer at Ad Scientiam.
"Disability worsening in MS has been recently redefined and we now know that this progression can occur independently of relapses. With MS-DETECT, we have an opportunity to develop a digital solution to help detect and monitor the effects of smoldering disease, and evolve treatment goals for MS patients," explains Su-Peing Ng, Global Head of Medical Affairs - Specialty Care at Sanofi.
The study also aims to assess the MSCopilot(R) performance, safety, usability and satisfaction with the solution.
"Disease progression can be hard to detect in routine practice. I believe these novel digital biomarkers are key to help clinicians make appropriate treatment decisions and, ultimately, improve patients' care," said Prof. Patrick Vermersch (Lille, France), Coordinating Investigator and Chairman of the Study Steering Committee.
The MS-DETECT study will include 314 PwMS and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France. Several investigative sites have already been initiated in North America and Europe and first patients are expected to participate in the study during Q3 2023.
Check our LinkedIn, Facebook, Instagram pages or visit adscientiam.com
Contact Information
Saad Zinai
Chief Medical Officer
szinai@adscientiam.com
+33768008666
Matthieu Lamy
President
mlamy@adscientiam.com
+33768008666
話題 Press release summary
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network
|
|
|
|
|
|
 |
|
Latest Press Releases
Kincora and AngloGold Ashanti Exploration Expands and Upgrades Nevertire with Drilling Recommenced
Feb 10, 2026, 19:29 HKT/SGT
|
|
|
EssexBio Bolsters Commitment to Ophthalmology Innovation at APAO 2026 in Hong Kong
Feb 10, 2026, 18:14 HKT/SGT
|
|
|
Honda Works Partner Aston Martin Aramco Formula One(TM) Team Unveils Livery of "AMR26" F1(TM) Machine Equipped with Honda Power Unit Ahead of the 2026 Race Season
Tuesday, February 10, 2026 5:25:00 PM
|
|
|
CTF Life+ Announces Winners of Financial Empowerment Case Competition, Innovative Platform Advances Intergenerational Inclusion
Feb 10, 2026, 17:02 HKT/SGT
|
|
|
Honda to Make Organizational Changes to Further Enhance Competitiveness its Motorcycle, Automobile and Power Products Business
Tuesday, February 10, 2026 4:53:00 PM
|
|
|
KS Energy and Hitachi Collaborate on Extra-High Voltage Battery Energy Storage System
Tuesday, February 10, 2026 1:15:00 PM
|
|
|
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Tuesday, February 10, 2026 12:34:00 PM
|
|
|
Spritzer EcoPark Gallops into the Year of the Horse with a Tradition-Inspired Chinese New Year Celebration
Feb 10, 2026, 11:49 HKT/SGT
|
|
|
Mint Signed MoU with Robotics Leader Rice Robotics to Pioneer Physical AI Solutions Across Asia
Feb 10, 2026, 09:43 HKT/SGT
|
|
|
NEC Exhibits at MWC Barcelona 2026, the World's Largest Mobile-Related Exhibition
Monday, February 9, 2026 8:18:00 PM
|
|
|
|
|
More Press release >> |
|
|
|
